Background. Tuberculous meningitis (TBM) is a severe complication of tuberculosis predominantly affecting young children. Early treatment is vital to prevent morbidity and mortality, emphasizing the importance of early diagnosis. The lack of sensitive methods for early diagnosis is the most common cause of delay. Attempts have been made to develop simplified tests for tuberculosis, but their diagnostic power remains poor. The clinical picture of TBM is mainly driven by the host's immune response to Mycobacterium tuberculosis; therefore, identification of disease-specific biomarkers may have diagnostic and therapeutic value and improve our understanding of its pathogenesis.
A third of the world's population is currently infected with Mycobacterium tuberculosis, and each year >1.5 million people die from tuberculosis [1] . Central nervous system (CNS) involvement occurs in approximately 1% of all cases of tuberculosis, among which cases of tuberculous meningitis (TBM) are the most severe, frequently occurring during early childhood [2] . The hematogenous transmission of bacilli from a primary pulmonary focus can lead to the development of a caseous granuloma-termed a Rich focus-in the meninges, adjacent brain tissue, or ventricular ependyma. Rupture of a Rich focus into the subarachnoid space causes the clinical features of TBM. In most cases, TBM develops within a few months of the primary infection [3] . The outcome of TBM is often poor despite adequate antituberculosis therapy. Early treatment initiation is the most significant factor affecting morbidity, mortality, and healthcare costs, emphasizing the importance of early diagnosis [4] .
Despite the severity of TBM, the cellular and molecular mechanisms underlying its pathophysiology are poorly understood [5] . A successful host response to an invading pathogen requires precise coordination of the components of the immune system [6] . Many of the signs, symptoms, and sequelae of TBM result from an immunologically directed inflammatory response to the infection [7] . Alterations in cytokine levels in patients with TBM can affect the function of the immune system and directly impact the course of TBM. In particular, the balance between pro-and anti-inflammatory cytokines may play an important role in disease progression [7] . Several pro-and anti-inflammatory cytokines (eg, tumor necrosis factor [TNF] α, interferon [IFN] γ, interleukin [IL] 1β, IL-6, IL-8, and IL-10) are upregulated in the cerebrospinal fluid (CSF) of patients with TBM compared with other types of meningitis [5, [8] [9] [10] [11] [12] [13] . A disease-specific host inflammatory response to TBM has been suggested but has not been thoroughly investigated [14] .
Using emergent statistical techniques, such as unsupervised hierarchical clustering (UHC) analysis, principal component analysis (PCA), and pathway analysis, we investigated the disease-specific biomarker expression profile of childhood TBM. We also evaluated the value of biomarker-based diagnostic prediction models for TBM.
METHODS

Study Population and Case Definition
We conducted a prospective hospital-based cohort study of children aged 3 months to 13 years, with symptoms and signs suggestive of meningitis, admitted to Tygerberg Hospital, Cape Town, South Africa, between November 2009 and November 2012. The symptoms and signs of meningitis included 1 or more of the following: headache, irritability, vomiting, fever, neck stiffness, convulsions, focal neurological deficits, altered consciousness, and lethargy. All children with suspected meningitis were classified into the TBM group or non-TBM group according to the diagnostic criteria proposed by Marais et al [15] .
Microbiological Assessment of CSF
In patients with suspected TBM, we performed auramine staining for direct fluorescence microscopy, BACTEC MGIT 960 Mycobacterial Detection System (Becton Dickinson and Company-Diagnostic Systems) culture, and 2 commercial nucleic acid amplification tests (NAATs): the GenoType MTBDRplus (Hain Life Science GmbH) and Xpert MTB/RIF (Cepheid) assays. All tests were performed according to the manufacturers' guidelines. Gram staining, Indian ink staining, and blood cultures were undertaken in all cases as part of routine care. A polymerase chain reaction (PCR) assay for viruses, including a herpes virus panel, enterovirus, and mumps virus, was performed when viral meningitis (VM) was suspected.
TBM Group
TBM was classified as "definite" when acid-fast bacilli were evident in, M. tuberculosis was cultured from, or M. tuberculosis was detected by 1 of the 2 commercial NAATs in the CSF of a patient with symptoms or signs suggestive of the disease. TBM was classified as "probable" when patients had a diagnostic score ≥12 when cerebral imaging was available and ≥10 when imaging was unavailable. TBM was classified as "possible" when a patient had a diagnostic score of 6-11 when cerebral imaging was available and 6-9 when imaging was unavailable. Diagnostic scores were based on the uniform clinical case definition of Marais et al [15] .
Non-TBM Group
The non-TBM group included bacterial meningitis (BM), VM, and no meningitis (NoM). BM was identified when either a bacterial pathogen was confirmed by microscopy and/or culture or the CSF examination showed at least 1 of the following: turbid appearance, leukocytosis of >100 cells/µL in isolation, or leukocytosis 10-100 cells/µL and either elevated protein >1 g/L or CSF glucose <50% of serum glucose [16] . VM was diagnosed when either a viral pathogen was confirmed by PCR or the clinical outcome was favorable with only supportive and/or antiviral therapy and CSF leukocyte count of ≥10 ×10 6 /L and other causes of meningitis were excluded [17, 18] . When an alternative cause was identified that explained the clinical presentation together with a leukocyte count in the CSF <5 × 10 6 /L, a diagnosis of "no meningitis" was made.
Sample Preparation
Blood and CSF samples were collected from all children with suspected meningitis during a routine diagnostic workup. All serum and CSF samples were centrifuged, and the supernatant was aliquoted into sterile polypropylene microtubes and stored at −80°C until use. CSF supernatant was passed through a hydrophilic Durapore polyvinylidene difluoride filter membrane (MultiScreen HTS -GV plate 0.22 µm; EMD Millipore Corporation).
Multiplex Cytokine and Chemokine Analysis
A panel of 27 host biomarkers in serum and CSF samples was measured by the Luminex multiplex bead array technology (Bio-Rad Laboratories). The panel included IL-1β, IL-1 receptor antagonist (IL-1RA), IL-2, IL-4 through IL-10, IL-12 ( p70), IL-13, IL-15, IL-17, IFN-γ, TNF-α, macrophage inflammatory protein (MIP) 1α, MIP-1β, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, eotaxin, basic fibroblast growth factor (bFGF), monocyte chemotactic protein 1, regulated upon activation normal T-cell expressed and secreted (RANTES), IFN-γ-induced protein (IP) 10, platelet derived growth factor BB, and vascular endothelial growth factor (VEGF). Prior to analysis, serum samples were diluted 1:4 with the sample diluent provided in the kit as recommended by the manufacturer. Assays were read on the Bio-Plex 200 platform, and the Bio-Plex Manager software 6.0 was used for bead acquisition and analysis.
Cathelicidin LL-37
The concentration of cathelicidin LL-37 in serum and CSF samples was assessed using an enzyme-linked immunosorbent assay kit (USCN Life Science). The manufacturer's protocol was followed and serum samples were diluted 1:500 with phosphate-buffered saline. Initially, the intra-assay coefficient of variation (CV) for cathelicidin LL-37 measurements was high but after the introduction of 2 extra washes, the intra-assay CV was <10%.
Statistical Analysis
Statistical analyses were performed using SPSS software version 20, GraphPad Prism version 4.0, and R version 3.0.1 [19] . Contingency tables were analyzed using the χ 2 or Fisher exact tests. Odds ratios with 99% confidence intervals (CIs) were calculated to measure the effect size. Median values were compared using the Mann-Whitney test, and means were compared using the unpaired Student t test. Pairwise comparisons of nonparametric data were performed using the Kruskal-Wallis test. UHC analysis of biomarkers in CSF and serum, heat map generation, and PCA were performed using Qlucore Omics Explorer software. Biological pathway analysis was performed using Ingenuity Pathway Analysis. For the diagnostic prediction model, multivariable logistic regression analysis was used. Restricted cubic spline curve analysis was done to evaluate linearity of the factors. As none of the selected biomarkers showed linearity and sample size was limited, variables were dichotomized using the maximum value of the Youden index (J = sensitivity + specificity -1) as the cutoff.
Stepwise backward selection based on the Wald test (with P = .10 as the cutoff ) was used to select variables. All possible combinations of the individual predictors were evaluated. The goodness of fit of the model was tested with the Hosmer-Lemeshow test. The receiver operating characteristic (ROC) curve based on the predicted probabilities of the model was calculated. Area under the curve (AUC), sensitivity, specificity, and positive and negative predictive values were calculated. Bootstrapping techniques were used for internal validation of the prediction models.
All measurements were conducted in duplicate, and the calculated mean of the measurements was used in the analyses. Laboratory personnel were blinded to the clinical information associated with the samples. In all analyses, P < .01 was considered statistically significant unless otherwise stated.
Ethical Approval
The study was approved by the Human Research Ethics Committee of Stellenbosch University (study number N09/10/265). Written informed consent was obtained from all patients or their caregivers.
RESULTS
Baseline Characteristics
One hundred and forty-six participants with suspected meningitis were eligible for analysis. We analyzed CSF and serum samples from 56 patients with and 55 patients without TBM (Figure 1 ). Of the children categorized as having VM (n = 25), 18 had viral pathogens detected by PCR in their CSF. Six of 10 children with BM had positive CSF cultures. The NoM group Table 1 . Altered consciousness, focal neurological deficits, and symptom duration >5 days were statistically significant more present in the TBM group. Table 2 comprises a detailed description of the TBM group. Baseline concentrations of the 28 soluble mediators in serum and CSF of TBM and non-TBM cases are presented in Figure 2 . Subgroup analysis identified significantly elevated concentrations of IL-13, VEGF, and cathelicidin LL-37 (P < .05), and a lower concentration of IL-17, in the CSF of patients with TBM compared to that of patients with VM and BM. In the serum of patients with TBM, concentrations of IL-17, cathelicidin LL-37, IFN-γ, and bFGF were significantly elevated (P < .05) compared with that of patients with VM and BM. These significant differences are detailed in Supplementary Table 1 . Subgroup analysis (Kruskal-Wallis test) of the TBM group did not show any significant difference in biomarker expression in CSF and serum between definitive, probable, and possible TBM cases. Eight TBM patients received antimicrobial therapy (including adjunctive corticosteroids) prior to lumbar puncture. No significant differences were found in biomarker expression in CSF or serum between these patients and those who did not receive antimicrobial therapy prior to lumbar puncture.
Unsupervised Hierarchical Clustering and PCA
To identify a TBM-specific biomarker profile, we performed UHC analysis and PCA. Significant clustering of patients with TBM was evident in the analysis of CSF samples ( Figure 3A ), but not serum samples. The results of UHC analysis of CSF samples were confirmed by PCA ( Figure 3B ). To determine the disease-specific biomarker signature of CSF, we calculated the grouped medians of each type of meningitis (TBM, VM, and BM) and the NoM group, and repeated UHC analysis. Highly significant distinct biomarker profiles were found to exist in the 4 subgroups ( Figure 4 ). UHC analysis of the TBM group did not show significant clustering of the 3 TBM subgroups (definitive, probable, and possible TBM) in CSF and serum samples.
Ingenuity Pathway Analysis
To understand the biological relevance of the biomarkers differentially expressed in the CSF of patients with TBM, BM, and VM, we performed ingenuity pathway analysis. Pathways associated with IL-17 signaling, hypercytokinemia, and communication between immune cells were relevant to all 3 types of meningitis. However, the relative abundance of markers linked to pathways associated with pathogenesis of multiple sclerosis (MS), vitamin D receptor (VDR)/retinoid X receptor (RXR) activation, and CC chemokine receptor 5 (CCR5) signaling in macrophages were greater in TBM than in BM or VM. Four markers involved in pathways associated with MS were upregulated in the CSF of patients with TBM (MIP-1α, MIP-1β, RANTES, and IP-10); however, in patients with BM, only RANTES, and in patients with VM, only MIP-1β, were upregulated. Similarly, the relative abundance of cytokines involved in the VDR pathway was greater in patients with TBM (cathelicidin LL-37, RANTES, IP-10, and IFN-γ) compared to patients with BM (RANTES and IL-2) and VM (granulocyte colony-stimulating factor, IFN-γ, and IL-2). Three markers in patients with TBM (MIP-1α, MIP-1β, and RANTES) were associated with CCR5 signaling in macrophages, whereas only 1 of these molecules was present in relatively high abundance in patients with BM (RANTES) and VM (MIP-1β). This analysis suggests that distinct signaling pathways are activated in TBM, BM, and VM; however, some discretion in drawing conclusions from this analysis is necessary as the BM group is relatively small in numbers (n = 10). 
Diagnostic Model for TBM
A TBM-specific biomarker signature was found in CSF samples by UHC, PCA, and pathway analysis; therefore, we evaluated a biomarker-based diagnostic model for TBM. CSF biomarkers with significant differences in expression between TBM and the other meningitis subtypes (VM and BM) were used for this analysis (Supplementary Table 1 ). The final diagnostic model consisted of a combination of 3 biomarkers: IL-13, Table 3 . The association of the 3 biomarkers used in the diagnostic model with clinical characteristics of TBM patients ( Table 2) was evaluated with nonparametric testing. VEGF concentrations in CSF were significantly higher in patients with CSF protein concentration >1 g/L (P = .009), hydrocephalus (P = .001), basal meningeal enhancement (P = .005), and precontrast basal hyperdensity (P = .009). IL-13 levels were significantly higher (P = .002) in patients with CSF glucose <2.2 mmol/L.
DISCUSSION
We evaluated the biomarker expression profile of children with signs and symptoms suggestive of meningitis by investigating 28 biomarkers in their CSF and serum with multiple statistical methods. Using UHC and PCA, we identified a highly specific biomarker pattern in the CSF of patients with TBM compared with other types of meningitis. This biomarker pattern suggests a disease-specific host immune response, and could be of diagnostic and therapeutic value. Pathway analysis provided insight into the pathways upregulated in TBM. In the CSF of patients with TBM, the relative abundance of cytokines and chemokines involved in pathways related to the pathogenesis of MS (including CCR5 signaling in macrophages) and VDR/RCR activation were greater than in the CSF of patients with BM or VM. MS is a chronic demyelinating disease of the CNS with several diverse pathogenic mechanisms. Influx of activated T cells and macrophages into the CNS is considered an important step in MS development. Release of proinflammatory cytokines by T helper (Th) 1 cells and macrophages triggers a chain of events, resulting in the formation of demyelinated plaques and axonal damage [22] . A network of chemokines and chemokine receptors, including MIP-1α, MIP-1β, RANTES, IP-10, and CCR5, may influence the trafficking of immune cells and their transfer to lesion sites, and is a potential target for the treatment of MS [22] . The upregulation of MS-related signaling in TBM suggests that similar treatment modalities could affect the sequelae of TBM. The active form of vitamin D, 1,25-dihydroxyvitamin D 3 , has physiological functions that extend beyond its classical role Grouped medians per subgroup were taken to illustrate the differences in biomarker expression profiles between the groups. Abbreviations: FGF, fibroblast growth factor; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP, IFN-γ-induced protein; MCAF, monocyte chemotactic and activating factor; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF, platelet derived growth factor BB; RANTES, regulated upon activation normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. Figure 3 continued. yellow = non-TBM), suggesting that patients within each subcluster probably share the same origin. Significant clustering of TBM cases is seen. B, Three-dimensional representation of principal component analysis of patients with and without TBM. Each dot represents 1 participant based on the values of all biomarkers studied. The percentage of variance is depicted on 3 axes. The distance in space between each dot represents the relatedness between each individual. Visual clustering of TBM cases is seen. Abbreviations: FGF, fibroblast growth factor; GCSF, granulocyte colonystimulating factor; GMCSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP, IFN-γ-induced protein; MCAF, monocyte chemotactic and activating factor; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF, platelet derived growth factor BB; RANTES, regulated upon activation normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. in calcium homeostasis and bone metabolism. Vitamin D deficiency is associated with inflammatory diseases and disorders with long latency periods, such as MS, rheumatoid arthritis, diabetes, and tuberculosis [23, 24] . The involvement of components of the VDR/RXR pathway supports a putative role for vitamin D in the pathogenesis of TBM [25] and is reminiscent of autoimmune diseases, such as MS.
The current reference standard for diagnosing TBM is the visualization of acid-fast bacilli in and/or culture of M. tuberculosis from the CSF. Mycobacterial culture of CSF may take up to 42 days to receive the results, and both methods have low sensitivities (10%-20%) [26, 27] . Many attempts have been made to develop simplified, mostly antigen-detection tests for tuberculosis but their diagnostic power remains poor [28] . Recently, a multidisciplinary group of tuberculosis experts proposed the essential criteria for a point-of-care test [29] . For extrapulmonary tuberculosis, the test should provide a sensitivity of 60% for probable TBM and a specificity of 95%. From this perspective, the diagnostic model presented here (sensitivity 52%, specificity 95%), although approaching that performance, falls short as a point-of-care test for the diagnosis of TBM. However, when compared to the current standard of diagnostic tests for childhood TBM, which have an even lower sensitivity, further refinement of this model appears important. Misra et al found infarctions to be associated with relative increased VEGF concentrations in the CSF of patients with TBM [30] . Interestingly we did not find this association but found clear associations with CSF protein concentration >1 g/L, hydrocephalus, basal meningeal enhancement, and precontrast basal hyperdensity. VEGF is a potent inducer of vascular permeability and angiogenesis [31] and is implicated in the pathogenesis of cerebral edema related to ischemia, trauma, tumors, and infection [32, 33] . Several studies report elevated levels of VEGF in the CSF [34] [35] [36] , suggesting that it may contribute to disruption of the blood-brain barrier and cerebral edema formation in TBM.
Our study has certain limitations. First, only 28 host markers were evaluated in this study, and numerous additional components are evaluable with multiplex cytokine arrays and should be included in future studies. Although internal validation in the same patient cohort is necessary and helpful, the ability to generalize the prediction model in an independent group of patients is necessary. Therefore, external validation with new data from an independent, comparable population at a different location should be performed prior to the implementation of this model in the clinical setting. Second, a case definition based on consensus of expert opinion was used for TBM diagnosis and could have caused misclassification bias. Interestingly, subgroup analysis of the 56 TBM patients revealed no immunological difference between definitive, probable, and possible TBM cases. Third, 8 TBM patients received antimicrobial therapy (including adjunctive corticosteroids) prior to lumbar puncture. For the last several years, corticosteroids have been used as adjunct to antituberculous drugs to improve outcome in human immunodeficiency virus-negative individuals [37] , but the exact mechanisms are still incompletely understood. Simmons et al [38] studied the kinetics of the inflammatory response in CSF and peripheral blood from 87 adults with TBM and found only significant modulation of acute CSF protein concentrations and marginally reduced IFN-y concentrations. Other immunological and routine biochemical indices of inflammation were unaffected, similar to the results presented in the study herein.
In conclusion, this study improves our understanding of the pathogenesis of TBM and may direct future strategies for the prevention of immunopathology associated with this devastating disease. Our data suggest that host biomarker signatures in the CSF have promising diagnostic applications and require urgent investigation.
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